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Abstract
Background/Aim. Identification of patients with arterial
hypertension and a possible onset of heart failure by de-
termining the concentration of N-terminal pro-B-type na-
triuretic peptide (NT-proBNP) enables timely intensifica-
tion of treatment and allows clinicians to prescribe and
implement optimal and appropriate care. The aim of this
study was to evaluate NT-proBNP in patients with long-
standing hypertension and in patients with signs of hy-
pertensive cardiomyopathy. Methods. The study involved
3 groups, with 50 subjects each: “healthy” persons (con-
trol group), patients with hypertension and normal left
ventricular systolic function (group 1) and patients with
longstanding hypertension and signs of hypertensive car-
diomyopathy with impaired left ventricular systolic func-
tion (group 2). We measured levels of NT-proBNP, C-
reactive protein and creatinine according to the manufac-
turer’s instructions. All the patients were clinically exam-
ined including physical examination of the heart with
blood pressure, pulse rate, electrocardiogram (ECG) and
echocardiogram. Results. Our results showed that the
determined parameters generally differed significantly
(Student’s t-test) among the groups. The mean (± SD) val-
ues of NT-proBNP in the control group, group 1 and group
2 were: 2.794 (± 1.515) pmol/L, 9.575 (± 5.449) pmol/L
and 204.60 (84,93) pmol/L, respectively. NT-proBNP cor-
related significantly with the determined parameters both in
the group 1 and the group 2. In the group 1, the highest
correlation was obtained with C-reactive protein (r =
0.8424). In the group 2, the highest correlation was obtained
with ejection fraction (r = -0.9111). NT-proBNP showed
progressive increase in proportion to the New York Heart
Association (NYHA) classification. The patients in the-
group 2 who belonged to the II and III NYHA class had
significantly higher levels of NT-proBNP than those in the
NYHA class I (ANOVA test, p = 0.001). Conclusion. The
obtained results suggest that NT-proBNP is a useful bio-
marker in the treatment of patients with longstanding hy-
pertension who are at risk for heart failure.
Key words:
natriuretic peptide; biological markers; hypertension;
cardiomyopathy, hypertrophic; risk assessment.
Apstrakt
Uvod/Cilj. Identifikacija bolesnika sa arterijskom hiperten-
zijom kojima preti srÿana slabost, pomoýu odreĀivanja kon-
centracije N-terminalnog pro-B-tipa natriuretskog peptida
(NT-proBNP) omoguýava kliniÿarima pravovremeno inten-
ziviranje leÿenja i propisivanje i sprovoĀenje optimalne i od-
govarajuýe nege, jer bolesnici sa hipertenzivnim srÿanim obo-
ljenjima imaju povišene koncentracije NT-proBNP. Cilj rada
bio je da se izvrši procena razlike u NT-proBNP kod bolesni-
ka sa hipertenzijom i normalnom sistolnom funkcijom  i onih
sa dugogodišnjom arterijskom hipertenzijom i znacima hi-
pertenzivne kardiomiopatije. Metode. U ispitivanje su bile
ukljuÿene tri grupe, svaka sa po 50 ispitanika: “zdrave” osobe
(kontrolna grupa), bolesnici sa arterijskom hipertenzijom i
normalnom sistolnom funkcijom leve komore (grupa 1) i bo-
lesnici sa dugogodišnjom arterijskom hipertenzijom i znacima
hipertenzivne kardiomiopatije sa oslabljenom sistolnom fun-
kcijom leve komore (grupa 2). Nivoi NT-proBNP, C-
reaktivnog proteina i kreatinina odreĀivani su prema uputstvu
proizvoĀaÿa. Svi bolesnici bili su kliniÿki pregledani ukljuÿu-
juýi fiziÿki pregled srca sa merenjem krvnog pritiska i pulsa,
elektrokardiogramom (EKG) i ehokardiogramom. Rezultati.
Naši rezultati pokazuju da se odreĀivani parametri generalno
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znaÿajno razlikuju (Studentov t-test) meĀu grupama. Srednje
(± SD) vrednosti NT-proBNT u kontrolnoj grupi, grupi 1 i
grupi 2 bili su: 2,794 (± 1,515) pmol/L, 9,575 (± 5,449)
pmol/L i 204,60 (84,93) pmol/L, redom. NT-proBNT zna-
ÿajno koreliše sa odreĀivanim parametrima u grupi 1 i u grupi
2. U grupi 1, najviša korelacija dobijena je sa C-reaktivnim
proteinom (r = 0,8424). U grupi 2, najviša korelacija dobijena
je sa ejekcionom frakcijom leve komore (r = -0,9111). Utvr-
Āeno je progresivno poveýanje NT-proBNT u odnosu na kla-
sifikaciju New York Heart Association (NYHA). Bolesnici u
grupi 2 koji su pripadali NYHA klasi II i III imali su znaÿajno
više vrednosti NT-proBNP od bolesnika u NYHA klasi I
(ANOVA test, p = 0,001). Zakljuÿak. Rezultati istraživanja
ukazuju na to da je NT-proBNP koristan biomarker u leÿenju
bolesnika sa dugogodišnjom arterijskom hipertenzijom koji-
ma preti zastojna srÿana slabost.
Kljuÿne reÿi:
natriuretski peptidi; biološki pokazatelji; hipertenzija;
kardiomiopatija, hipertrofiÿka; rizik, procena.
Introduction
Like other natriuretic peptides, N-terminal pro-B-type
natriuretic peptide (NT-proBNP) is  secreted from the heart
in response to cardiac hemodynamic stress mediated by vol-
ume and/or pressure overload 1. The identification of patients
with arterial hypertension with the onset of heart failure by
determining the concentration of NT-proBNP, enables timely
intensification of treatment and allows physicians to pre-
scribe and implement optimal and appropriate therapy 2–4.
The increase of NT-proBNP is related to the left ventricular
mass index, left ventricular hypertrophy and diastolic left
ventricular dysfunction. Concentrations of NT-proBNP in
the serum were not significantly increased in hypertensive
patients with the normal left ventricular geometry compared
to normotensive individuals 5, 6.
Heart failure is characterized by a dysfunctional natriu-
retic peptide system. Natriuretic peptides are semi-
quantitative markers of cardiac stress and heart failure, and
thus related to the extent of atrial, ventricular, and valvular
dysfunction 1. Diagnosis of heart failure in the primary stage
using only clinical criteria in 50% of cases gives false posi-
tive results 7, 8. Heart failure, especially in its early stages, is
difficult to diagnose. The most commonly applied method of
investigation to confirm the diagnosis of heart failure is
echocardiography, which offers structural and functional in-
formation about the heart. However, assessment of cardiac
function by echocardiography requires considerable time and
is expensive to use in daily practice. For clinicians there is a
legitimate medical requirement for a biomarker that would
be a reliable and objective test to identify hypertensive pa-
tients with the onset of heart failure 9–15.
Inflammatory markers are increased in chronic heart
failure, including C-reactive protein (CRP) 16. Additionally,
CRP predicts morbidity and mortality in patients with estab-
lished heart failure 17–19.
NT-proBNP has a principal effect on the kidney, pro-
moting tubular natriuresis and diuresis. As with heart failure
evaluation, knowledge of the cardiac and noncardiac factors
that influence the NT-proBNP concentration is necessary.
Therefore, proper study of the evaluation of heart failure
must include the estimation of glomerular filtration rate or
determination of creatinine 20.
The aim of this study was to compare the concentra-
tions of NT-proBNP with the parameters of clinical exami-
nation and biomarkers (systolic blood pressure, diastolic
blood pressure, ejection fraction, CRP and creatinine) in pa-
tients with hypertension, and to determine the relationship
between NT-proBNP and the New York Heart Association
(NYHA) classification in patients with longstanding hyper-
tension with signs of hypertensive cardiomyopathy.
Methods
We measured all the biomarkers according to the manu-
facturer’s instructions. The analytical performance of the
methods has been evaluated and described elsewhere 21. The
study included three groups, each with 50 subjects: “healthy”
persons (control group), patients with hypertension and nor-
mal systolic left ventricular function (group 1) and patients
with longstanding hypertension and signs of hypertensive
cardiomyopathy with impaired systolic function of the left
ventricle (group 2). The control group included healthy
adults of both sexes subjected to the routine systematic
health examination at the Institute of Occupational Medicine,
Military Medical Academy in Belgrade, Serbia and voluntary
blood donors at the Institute of Transfusion, Military Medi-
cal Academy in Belgrade, Serbia. The patients of the group 1
and group 2 were treated at the Clinic of Cardiology, Mili-
tary Medical Academy and had the diagnosis of these dis-
eases. These patients were clinically examined including
physical examination of the heart with blood pressure, pulse
rate, electrocardiogram (ECG) and echocardiogram. Left
ventricular ejection fraction (EF) was derived from 2-
dimensional echocardiography. Blood samples were taken
from all the subjects and the serum was separated from cells
within 60 minutes of collection and centrifuged at 2028g
(4000 rpm) for 10 min. We measured all the biomarkers in a
single batch at the Institute of Medical Biochemistry, Mili-
tary Medical Academy. The study was approved by the in-
stitutional Ethics Committee, in compliance with the Hel-
sinki criteria. All the study participants gave written in-
formed consent.
All the biomarkers were measured according to the
manufacturer’s instructions. The analytical performance of the
methods has been evaluated and described elsewhere 21. Lev-
els of NT-proBNP were measured by a one-step enzyme im-
munoassay based on electrochemiluminescence technology on
the Elecsys® 2010 platform (Roche Diagnostics). The refer-
ence range, as reported by the manufacturer, was < 14.75
pmol/L. Levels of CRP were measured using the Behring BN
II Nephelometer (Dade Behring/Siemens Medical Solutions
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Diagnostics). The reference range, as reported by the manu-
facturer, was < 3 mg/L. Creatinine concentrations were meas-
ured by the kinetic alkaline picrate method (improved Jaffe re-
action) on a Dimension RxL Max analyzer (Dade Be-
hring/Siemens Medical Solutions Diagnostics). The reference
range, as reported by the manufacturer, was 53ҝ–115 ȝmol/L
(71ҝ–115 ȝmol/L for men and 53–ҝ88 ȝmol/L for women).
Adherence to Gaussian distributions was assessed using
the Kolmogorov-Smirnov test. The mean, standard deviation
(SD), Student’s t-test and Pearson’s test were used for statis-
tical analysis. All the probabilities were two tailed and p <
0.05 was regarded as significant. The 95% confidence inter-
val (CI) was also shown in reported data. The data were sta-
tistically analysed with the MedCalc®, Ver. 11.3.3.0 pack-
age (MedCalc Software, Mariakerke, Belgium).
Results
The control group included 25 women and 25 men aged
50–65 years (ʉ ± SD, 56.3 ± 4.20 years). The group 1 in-
cluded 19 women and 31 men aged 50–65 years (ʉ ± SD,
57.7 ± 4.57 years), and in the group 2 there were 17 women
and 33 men aged 50–65 years (ʉ ± SD, 58.1 ± 4.82 years).
Clinical and echocardiographic examinations were per-
formed in all patients in order to evaluate the NYHA-class
and the left ventricular EF.
The mean (SD) values of NT-proBNP, creatinine, CRP,
systolic blood pressure, diastolic blood pressure and in the
control group, group 1 and group 2 were presented in Tables
1–3. Comparison studies showed that levels of NT-proBNP
and systolic blood pressure were significantly higher in the
group 1 and the group 2 than in the control group, and also
higher in the group 2 than in the group 1. EF values were
significantly lower in the group 1 and in the group 2 than in
the control group, and also lower in the group 2 than in the
group 1. Levels of creatinine and diastolic blood pressure did
not differ significantly between the groups 1 and 2, while
CRP levels did not differ between the control group and the
group 1 (Tables 1–3, Figure 1).
In the group 2, the patients were divided into three sub-
groups according to the NYHA classification. The number of
patients in the group 2 in different NYHA classes was: I (n =
29.58%), II (n = 16.32%) and III (n = 5.10%). The group 2
subjects that belonged to the NYHA class II and III had sig-
nificantly higher levels of NT-proBNP than those in the
NYHA class I (ANOVA test, p = 0.001). The levels of NT-
proBNP were also significantly higher in the NYHA class I
than in the control group (Tables 4–5, Figure 2).
The distribution of data in all the groups was generally
normal, so the Pearson’s test was used for correlation analysis.
The values for the correlation coefficient (r), the confidence
interval for r (95% CI) and p are given in Tables 6 and 7.
Table 1
Comparison analysis data for the determined parameters between the control group and the group 1
Parameter Control group Group 1 p value
NT-proBNP (pmol/L) 2.794 (1.515) 9.575 (5.449) < 0.0001*
Creatinine (ȝmol/L) 85.5 (12.4) 90.9 (13.7) 0.0414*
CRP (mg/L) 2.64 (1.02) 2.73 (1.07) 0.6609
Systolic blood pressure (mm/Hg) 126.9 (9.5) 146.3 (9.4) < 0.0001*
Diastolic blood pressure (mm/Hg) 81.2 (4.9) 92.2 (5.0) < 0.0001*
EF (%) 63.2 (4.5) 60.8 (5.3) < 0.0001*
Data are presented as means (± SD); * statistically significant difference (Student’s t-test); NT-proBNP–N–terminal pro B-type
natriuretic peptide; CRP – C-reactive protein; EF – ejection fraction.
Table 2
Comparison analysis data for the determined parameters between the control group and the group 2
Parameter Control group Group 2 p value
NT-proBNP (pmol/L) 2.794 (1.515) 204.60 (84.93) < 0.0001*
Creatinine (ȝmol/L) 85.5 (12.4) 90.9 (14.3) 0.0464*
CRP (mg/L) 2.64 (1.02) 4.17 (1.03) < 0.0001*
Systolic blood pressure (mm/Hg) 126.9 (9.5) 150.5 (6.3) < 0.0001*
Diastolic blood pressure (mm/Hg) 81.2 (4.9) 95.5 (11.0) < 0.0001*
EF (%) 63.2 (4.5) 48.0 (6.0) < 0.0001*
Data are presented as means (± SD); * statistically significant difference (Student’s t-test); NT-proBNP–N–terminal pro B-type
natriuretic peptide; CRP – C-reactive protein; EF – ejection fraction.
Table 3
Comparison analysis data for the determined parameters between the group 1 and the group 2
Parameter Group 1 Group 2 p value
NT-proBNP (pmol/L) 9.575 (5.449) 204.60 (84.93) < 0.0001
Creatinine (ȝmol/L) 90.9 (13.7) 90.9 (14.3) 1.000
CRP (mg/L) 2.73 (1.07) 4.17 (1.03) < 0.0001
Systolic blood pressure (mm/Hg) 146.3 (9.4) 150.5 (6.3) 0.0099
Diastolic blood pressure (mm/Hg) 92.2 (5.0) 95.5 (11.0) 0.0558
EF (%) 60.8 (5.3) 48.0 (6.0) < 0.0001
Data are presented as means (± SD); * statistically significant difference (Student’s t-test); NT-proBNP–N–terminal pro B-type
natriuretic hormone; CRP – C-reactive protein; EF – ejection fraction.
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Fig. 1 – Distribution of N–terminal pro B-type natriuretic peptide (NT-proBNP), ejection fraction (EF), systolic and diastolic
blood pressure, creatinine and C-reactive protein (CRP) value in the control group, the group 1 and the group 2
Table 4
Comparison analysis data for the determined parameters in the group 2 in regard to the
New York Heart Association (NYHA) classes
NYHAParameter p values class mean
I 147.4 (II) (III)
II 367.2 (I)NT-proBNP (pmol/L) < 0.001*
III 336.4 (I)
I 89.5
II 91.2Creatinine (ȝmol/L) 0.447
III 98.4
I 3.69 (II) (III)
II 4.60 (I) (III)CRP (mg/L) < 0.001*
III 5.58 (I) (II)
I 148.3 (II) (III)
II 152.5 (I)Systolic blood pressure (mm/Hg) 0.004*
III 157.0 (I)
I 93.4
II 97.5Diastolic blood pressure (mm/Hg) 0.251
III 101.0
I 52.1 (II) (III)
II 43.1 (I)EF  (%) < 0.001*
III 40.0 (I)
The numbers in brackets [(I), (II), (III)] indicate a NYHA class which was significantly different from the
present NYHA class; * statistically significant difference (ANOVA test); NT-proBNP–N–terminal pro B-
type natriuretic peptide; CRP – C-reactive protein; EF – ejection fraction.
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Table 5
Comparison analysis data for the determined parameters between the control group and the
NYHA I subgroup in the group 2
Parameter Control group NYHA I p values
NT-proBNP (pmol/L) 2.794 (1.515) 147.30 (49.58) < 0.0001*
Creatinine (ȝmol/L) 85.5 (12.4) 89.5 (15.9) 0.2197
CRP (mg/L) 2.64 (1.02) 3.69 (0.85) < 0.0001*
Systolic blood pressure (mm/Hg) 126.9 (9.5) 148.3 (6.2) < 0.0001*
Diastolic blood pressure (mm/Hg) 81.2 (4.9) 93.4 (6.3) < 0.0001*
EF (%) 63.2 (4.5) 52.1 (4.0) < 0.0001*
Data are presented as means (± SD); * statistically significant difference (Student’s t-test); NT-proBNP–N–terminal pro
B-type natriuretic peptide; CRP – C-reactive protein; EF – ejection fraction.
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Fig. 2 – Distribution of N–terminal pro B-type natriuretic peptide (NT-proBNP), ejection fraction (EF), systolic and diastolic
blood pressure, creatinine and C-reactive protein (CRP) value in the group 2 according to the NYHA classification
In the group 1, NT-proBNP correlated significantly with
all the determined parameters (Table 6). The highest correlation
was obtained between NT-proBNP and CRP (r = 0.8424, 95%
CI 0.7369–0.9079). In the group 2, NT-proBNP also correlated
significantly with all the parameters, except with creatinine (Ta-
ble 7). The highest correlation was obtained between NT-
proBNP and EF (r = -0.9111, 95% CI -0.9489 – -0.8478).
Table 6
    The correlation of N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations
and the values of determined parameters in the group 1 (n = 50)
NT-proBNP (pmol/L)Parameter r 95%CI p values
Creatinine 0.3379 0.0657–0.5633 0.0164*
CRP 0.8424 0.7369–0.9079 < 0.0001*
Systolic blood pressure 0.7213 0.5542–0.8325 < 0.0001*
Diastolic blood pressure 0.4282 0.1701–0.6313 0.0019*
EF -0.7390 -0.8438 – -0.5800 < 0.0001*
* statistically significant correlation (Pearson’s test); CRP – C-reactive protein; EF – ejection fraction.
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Discussion
Elevated blood pressure causes left ventricular hyper-
trophy as an independent factor for the development of ar-
rhythmias, heart failure and sudden death. NT-proBNP now
appears to be an indicator of asymptomatic cardiac organ
damage in patients who eventually develop left ventricular
hypertrophy, left arterial dilation, atrial fibrillation, and left
ventricular systolic dysfunction 22, 23.
This study aimed to assess the characteristics of
NTproBNP, CRP, creatinine and the parameters of clinical
examination (systolic blood pressure, diastolic blood pres-
sure) in patients with longstanding hypertension and in pa-
tients with signs of hypertensive cardiomyopathy.
NT-proBNP showed good sensitivity in detecting heart
failure in the group of patients with hypertension and car-
diomyopathy. A single measurement of NT-proBNP at the
time of hospital admission provides important information
about left ventricular EF in patients with hypertension 1.
Comparison with the group of patients with hypertension
showed that levels of this natriuretic peptide correlated
equally (p < 0.001) with systolic blood pressure, EF, CRP
and creatinine. Piechota et al. 24 reported that NT-proBNP
correlated equally well with the clinical and echocardio-
graphic parameters of chronic heart failure, which makes
them equally adequate in the biochemical staging of chronic
heart failure severity.
Several clinical trials have shown that NT-proBNP is a
sensitive marker of cardiac function whose rise indicates the
presence of heart failure, and on the other hand, when the
level of NT-proBNP is within the normal limits, it excludes
cardiac dysfunction. The level of NT-proBNP is directly cor-
related with the severity of disease (I–IV NYHA classifica-
tion) 9, 19. In our study patients in the group with NYHA class
II and III had significantly higher plasma concentrations of
NT-pro-BNP, hsCRP and lower EF (p < 0.001). Seino et
al. 10 also evaluated NT-proBNP in 105 patients with chronic
heart failure, and a progressive increase in NT-proBNP in
proportion to the NYHA classification was confirmed in this
study.
It was shown that CRP is elevated in patients with
chronic heart failure and its prognostic value was established
in these patients 16–18. Our study confirms these findings. The
mean CRP of patients in the group 2 (patients with hyperten-
sion and cardiomyopathy) was 4.17 ± 1.03 mg/L, and 2.73 ±
1.07 in the group 1 (patients with hypertension) (p < 0.0001).
Because we had excluded patients with infections or inflam-
matory diseases, our data suggest that inflammation was re-
lated to heart failure and not to external factors.
Conclusion
This study supports the importance of NT-proBNP
measurement in patients with longstanding hypertension with
signs of hypertensive cardiomyopathy. It shows that
NTproBNP correlates significantly with EF. NT-proBNP
showed a progressive increase in proportion to the NYHA
classification. These data suggest that NT-proBNP is a useful
biomarker in the treatment of patients with longstanding hy-
pertension who are at risk for heart failure.
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